Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

247.16USD
21 Feb 2017
Change (% chg)

$-0.19 (-0.08%)
Prev Close
$247.35
Open
$247.35
Day's High
$249.84
Day's Low
$246.40
Volume
2,555,443
Avg. Vol
4,800,596
52-wk High
$301.32
52-wk Low
$184.50

AGN

Chart for AGN

About

Allergan plc is a global pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. The Company is also is focused on developing, manufacturing and commercializing select over-the-counter (OTC) products. The... (more)

Overall

Beta: 1.15
Market Cap(Mil.): $92,389.74
Shares Outstanding(Mil.): 375.08
Dividend: 0.70
Yield (%): 1.14

Financials

  AGN Industry Sector
P/E (TTM): -- 28.45 29.35
EPS (TTM): -3.12 -- --
ROI: -- 13.47 12.97
ROE: -- 14.36 14.11

BRIEF-Allergan says Goldman Sachs Group reported 6.3 pct passive stake in co as of Dec. 31 - SEC filing

* The Goldman Sachs Group Inc reports 6.3 percent passive stake in Allergan Plc as of dec. 31, 2016 - sec filing Source text: (http://bit.ly/2knWz9s) Further company coverage:

Feb 14 2017

Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion

Botox maker Allergan Plc <AGN.N,> agreed to pay $2.48 billion in cash for Zeltiq Aesthetics Inc, adding a system that it says helps people slim down by freezing fat away to the company's line-up of aesthetic products.

Feb 13 2017

UPDATE 4-Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 bln

Feb 13 Botox maker Allergan Plc <AGN.N,> agreed to pay $2.48 billion in cash for Zeltiq Aesthetics Inc, adding a system that it says helps people slim down by freezing fat away to the company's line-up of aesthetic products.

Feb 13 2017

Allergan adds ice and a slice to M&A cocktail

NEW YORK (Reuters Breakingviews) - Allergan has added ice and a slice to its M&A cocktail. The drug company is paying just under $2.5 billion for Zeltiq Aesthetics and its diet-avoiding, fat-freezing tech. It sounds a wackier play than the dozen deals Allergan struck last year. But vain customers pay cold cash for the treatment, making it less speculative than other acquisitions, like gene therapy.

Feb 13 2017

CORRECTED-UPDATE 2-Allergan to buy Zeltiq Aesthetics for about $2.48 bln

Feb 13 Botox maker Allergan Plc said it would buy body-contouring product maker Zeltiq Aesthetics Inc for about $2.48 billion, adding muscle to its line-up of products used to fight fat and smoothen wrinkles.

Feb 13 2017

BRIEF-Allergan agrees to acquire Zeltiq for $2.48 bln

* Allergan has agreed to acquire Zeltiq for $56.50 per share, or $2.475 billion

Feb 13 2017

Allergan agrees to buy Zeltiq for about $2.48 bln

Feb 13 Allergan Plc on Monday said it would buy Zeltiq Aesthetics Inc for about $2.48 billion to gain access to its flagship body contouring technology.

Feb 13 2017

BRIEF-Third Point LLC takes share stake in JPMorgan, Bank of America - SEC Filing

* Third Point Llc dissolves share stake in Allergan Plc - SEC Filing

Feb 10 2017

Allergan says U.S. tax reform unlikely in 2017, sees strong year

Allergan Plc Chief Executive Brent Saunders said on Wednesday he does not anticipate U.S. tax reforms this year and that an import tax could hurt the Dublin-based drugmaker.

Feb 08 2017

UPDATE 3-Allergan says U.S. tax reform unlikely in 2017, sees strong year

* Shares rise as much as 2.6 pct (Adds detail, analyst comment)

Feb 08 2017

More From Around the Web

Earnings vs. Estimates